News / 08 Jun 2021
Summit Therapeutics set to join Russell 3000® Index
News / 03 Jun 2021
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
News / 18 May 2021
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike.
Chairman & Chief Executive Officer